Previous close | 1.6900 |
Open | 1.6500 |
Bid | 1.4600 x 100 |
Ask | 1.5200 x 300 |
Day's range | 1.4750 - 1.6700 |
52-week range | 1.3000 - 11.9200 |
Volume | |
Avg. volume | 660,301 |
Market cap | 44.777M |
Beta (5Y monthly) | -0.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Potential Immuneering Corporation ( NASDAQ:IMRX ) shareholders may wish to note that the Director, Peter Feinberg...
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.